ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23% Market Closed
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Net Change in Cash
$70m
CAGR 3-Years
-5%
CAGR 5-Years
13%
CAGR 10-Years
34%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Net Change in Cash
-CA$4.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Net Change in Cash
$19.7m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
38%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Net Change in Cash
-$9.3m
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Net Change in Cash
CA$216.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-25%
Spectral Medical Inc
TSX:EDT
Net Change in Cash
CA$735k
CAGR 3-Years
-40%
CAGR 5-Years
N/A
CAGR 10-Years
-21%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Net Change in Cash?
Net Change in Cash
70m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Net Change in Cash amounts to 70m USD.

What is ESSA Pharma Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
34%

The average annual Net Change in Cash growth rates for ESSA Pharma Inc have been -5% over the past three years , 13% over the past five years , and 34% over the past ten years .

Back to Top